Novel ADC Target Hunting in Pediatric AML – Module 4

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (4 of 5 Modules)

This activity provides an overview of key data and ongoing clinical trials investigating the development and use of antibody-drug conjugates (ADC) targeting different myeloid markers for the treatment of pediatric acute myeloid leukemia (AML).

Credit Expired

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Assess key data sets and ongoing clinical trials investigating antibody-drug conjugates for the treatment of acute myeloid leukemia (AML)

Activity Faculty

Soheil Meshinchi, MD, PhD

Full Member, Fred Hutchinson Cancer Center
Professor, Pediatrics
University of Washington
Seattle, WA

Featured RMEI CE Activities – Earn CE Credit(s)

Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant: A Clinical Forum®

1.25 CE Credit(s)

New Horizons in Food Allergy: Best Practices & Treatment Advances for Unmet Needs: A Clinical Transfers®

1.0 CE Credit(s)

Immunotherapy for NMSC: Key Insights for Oncology, Dermatology, and Infusion Nurses: A Clinical Transfers®